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Targeting TrkB signaling could represent a good therapeutic strategy to prevent obesity. In this issue of
Chemistry &Biology, Chan et al. report the efficacy of 7,8-DHT, a TrkB agonist, in preventing obesity in female
mice. The underlying molecular mechanisms behind this activity seem to involve increased energy expendi-
ture in skeletal muscle.Sustained imbalance between energy
intake and energy expenditure results
in obesity. Accordingly, most common
strategies to treat obesity are to reduce
food intake and/or increase energy
expenditure through means such as
physical exercise; however, these treat-
ments are not always effective and are
often faced with recidivation. Addition-
ally, physiology of obesity is complex,
and solutions based on life-style adjust-
ments might not be adequate for treat-
ment of all the cases. Maintenance
of systemic glucose and lipid homeosta-
sis involves multiple organs such as
brain, liver, pancreas, and skeletal mus-
cle. In particular, skeletal muscle func-
tion is a critical determinant of obesity
by regulating exercise capacity and en-
ergy metabolism. Skeletal muscle plays
important roles not only in the regulation
of glucose and fatty acid levels via
transport and oxidation, but also in the
secretion of myokines to influence endo-
crinal organs for subsequent changes in
metabolism (Pedersen and Febbraio,
2012). Importantly, skeletal muscle has
a higher respiration rate in mitochondria
than other tissues due to its oxygen-
consuming property. This makes it
more susceptible to impairment in oxida-
tive phosphorylation, which is associated
with obesity development. On the other
hand, some protons are transported to
the inner membrane of mitochondria via
uncoupling proteins (UCPs) to generate
heat instead of ATP, and this uncoupling
of respiration helps to keep a high meta-
bolic rate. The diminished uncoupling in
mitochondria also contributes to obesity
development (van den Berg et al.,
2011). Collectively, functional mitochon-dria in skeletal muscle are pivotal in
maintaining energy homeostasis.
Accumulating evidence shows that
impaired signaling of brain-derived neuro-
trophic factor (BDNF) and its receptor
TrkB promotes obesity by enhancing
appetite, which represents one of the
key mechanisms whereby energy meta-
bolism is hindered (Marosi and Mattson,
2014). Beyond controlling the feeding
behavior, BDNF was recently found to
be involved in energy metabolism in pe-
ripheral tissues. BNDF administration is
known to increase insulin production in
pancreatic beta cells, improve insulin
sensitivity in skeletal muscle, decrease
glucose production in hepatocytes, and
enhance glucose uptake in muscle and
liver (Marosi and Mattson, 2014). More-
over, local production of BDNF can be
induced by exercise stimulation in skeletal
muscle, indicating a role of BDNF in the
neuromuscular axis (Tsai et al., 2015).
Furthermore, BDNF stimulates activation
of AMPK, which is a key sensor for energy
metabolism and exercise endurance in
skeletal muscle (Matthews et al., 2009).
Taken together, impaired signaling of
BDNF in peripheral target organs such
as skeletal muscle might be associated
with development of obesity. BDNF, how-
ever, has a short half-life of less than
10 min in circulation and is poorly perme-
able through the blood-brain barrier
(BBB), which decreases its utility as a
therapeutic agent. Studies on BDNF
have been mostly focused on its transient
and local effects, rather than its chronic
and systematic impacts.
The study by Chan et al. (2015) in this
issue of Chemistry & Biology demon-
strates that activation of TrkB signalingChemistry & Biology 22, March 19, 2015prevents gender-dependent develop-
ment of obesity in female mice. First of
all, the authors confirm that a small mole-
cule TrkB agonist, 7,8-dihydroxyflavone
(7,8-DHF), is a useful alternative to
BDNF. Unlike BDNF, 7,8-DHF is much
smaller (254 Da versus 27 kDa for 7,8-
DHF versus BDNF, respectively), perme-
able through BBB, and orally active
(Jang et al., 2010). The prolonged supple-
mentation of 7,8-DHF had an antiobesity
effect while inducing TrkB expression
in hypothalamus, implicating that the
agonist is specifically working through
the TrkB pathway. Second, this study
defined a signaling pathway of TrkB in
skeletal muscle, as shown in Figure 1.
The most significant finding is that 7,8-
DHF upregulates mitochondrial uncou-
pling protein 1 (UCP1) and activates
AMPK/ACC (acetyl-CoA carboxylase) to
induce fat oxidation in skeletal muscle,
which represents an important pathway
to increase energy expenditure. Glucose
uptake was enhanced, along with
increased AKT and AMPK phosphory-
lation, which would also improve
glucose tolerance and insulin sensitivity.
Enhanced phosphorylation of ERK1/2
and AKT leads to phosphorylation and
activation of CREB, a transcription factor
required for expression of UCP1. Of
note, UCP1-overexpressing mice have
been shown to have augmented whole-
body energy expenditure, skeletal muscle
mitochondrial uncoupling, and attenuated
obesity and glucose intolerance in
response to a high fat diet (Li et al.,
2000). The antiobesity effect induced by
7,8-DHF might be largely attributed to
UCP1 upregulation. Finally, oral adminis-
tration of 7,8-DHF suppressed bodyª2015 Elsevier Ltd All rights reserved 311
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Figure 1. Skeletal Muscle-Centric Signaling Pathways Mediating the Obesity-Protective
Effects of TrkB
The TrkB agonist 7,8-DHF activates AKT and ERK1/2 activation. Activated AKT and ERK1/2 are known to
phosphorylate cAMP-responsive element binding protein (CREB). Once phosphorylated CREB binds to
CRE, transcription of uncoupling protein 1 (UCP1) is induced. Upregulation ofmitochondrial UCP1 is asso-
ciated with thermogenesis and activation of AMPK, an important sensor for maintaining energy homeosta-
sis. Activated AMPK inhibits substrate acetyl coA carboxylase (ACC) by phosphorylation, which leads to
increased lipid oxidation. On the other hand, AKT and AMPK have been implicated in glucose uptake in
skeletal muscle. Collectively, activation of the signaling network by 7,8-DHF/TrkB markedly increases
skeletal muscle-centric energy expenditure, which appears to be the molecular mechanism responsible
for reduced obesity.
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Previewsweight gain alongside improved insulin
sensitivity and glucose intolerance, which
was abolished in muscle-specific TrkB
knockout mice, establishing an intermedi-
ate role of TrkB in the antiobesity effect of
7,8-DHF. These transgenic mice can be
useful tools to study TrkB signaling in
skeletal muscle to better understand
detailed mechanisms for the prevention
of obesity. Of note, the antiobesity effect
of 7,8-DHF was observed only in females,
indicating gender-specific response to
this pathway. Given the lower skeletal
muscle mitochondrial ATP production312 Chemistry & Biology 22, March 19, 2015rate in women (Karakelides et al., 2010),
the augmentation of skeletal muscle mito-
chondrial function by TrkB signalingmight
be more effective in females. In addition,
part of the 7,8-DHF mechanism of action
might involve estrogen receptors. Further
studies to clarify this gender specificity
might prove beneficial in designing new
therapeutics effective for women. As a
separate note, unlike BDNF, 7,8-DHF did
not cause alteration of feeding behavior.
This finding may also be worthwhile for
future investigation. Taken together, the
antiobesity effect of 7,8-DHF/TrkB activa-ª2015 Elsevier Ltd All rights reservedtion appears attributed to increased
energy expenditure in skeletal muscle
through activation of mitochondrial un-
coupling, fatty acid oxidation, glucose up-
take, and possible heat production by
mitochondrial UCP1. This study by Chan
et al. (2015) paves the way to exploring
the therapeutic potential of the skeletal
muscle TrkB agonist in the prevention of
obesity.
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